Islet Transplantation Through an Indwelling Catheter in the Umbilical Vein
1 other identifier
interventional
12
0 countries
N/A
Brief Summary
Islet transplantation is one of the effective and promising options for type 1 diabetes mellitus treatment1-4. The liver is the primary target location for infusion and portal vein catheterization is generally used. Percutaneous transjugular, percutaneous transhepatic, laparoscopically transmesenteric and laparoscopically transumbilical approaches were often utilized to access the portal. Current islet infusion approach via portal vein of liver has various defects. Percutaneous trans-hepatic puncture is risk of possible severe hemorrhage and portal thrombosis. The laparoscopic entry techniques require longer surgical duration and have an increased rate of catheterization failure. Moreover, the catheters were not allowed to indwell for subsequent infusions. In the current study, the investigators aim to performed open surgery, catheterized the umbilical vein and infused islets into the portal vein. The catheter was indwelled for one month after surgery. Therapeutic effects, surgical parameters and complications were observed to evaluate feasibility and safety.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1
Started Jun 2008
Longer than P75 for phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedFirst Submitted
Initial submission to the registry
January 23, 2015
CompletedFirst Posted
Study publicly available on registry
February 20, 2015
CompletedFebruary 20, 2015
February 1, 2015
4.5 years
January 23, 2015
February 12, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
hemorrhage
1 month
Secondary Outcomes (4)
Infection
6 month
Exogenous insulin requirement
1 year
Glucose
1 year
C-peptide
1 year
Study Arms (1)
Umbilical vein
EXPERIMENTALumbilical vein catheterization
Interventions
A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
Eligibility Criteria
You may qualify if:
- Male and female patients age 18 to 60 years of age.
- Ability to provide written informed consent.
- Clinical history compatible with type 1 diabetes (T1DM) as defined by the WHO guidelines(2007) on the Diagnosis and classification of Diabetes Mellitus.
- manifest signs and symptoms that are severe enough to be incapacitating.
- Basal C-peptide\<0.5ng/mL
- patients with poor diabetes control (HbA1c \>7% but \<12%)
- progressive diabetic complications.
You may not qualify if:
- age \<18 years or \>60 years
- diabetic history \<5 years
- BMI\>27
- body weight \>80kg
- exogenous insulin requirement \>1 unit/kg/day
- severe anemia (male \<8g/dl, female \<7g/dl)
- low white blood cell count (\<3000/dl)
- liver dysfunction
- Symptomatic peptic ulcer disease
- Any malignancy
- Active infection including hepatitis B, hepatitis C, HIV, or TB
- panel reactive antibody \>20%
- Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Organ transplantation intitute
Study Record Dates
First Submitted
January 23, 2015
First Posted
February 20, 2015
Study Start
June 1, 2008
Primary Completion
December 1, 2012
Study Completion
December 1, 2013
Last Updated
February 20, 2015
Record last verified: 2015-02